Cited 0 times in
Alpha-fetoprotein-producing gastric cancer.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, R | - |
dc.contributor.author | Rha, SY | - |
dc.contributor.author | Ahn, JB | - |
dc.contributor.author | Shim, KY | - |
dc.contributor.author | Choi, JH | - |
dc.contributor.author | Lim, HY | - |
dc.contributor.author | Yoo, NC | - |
dc.contributor.author | Noh, SH | - |
dc.contributor.author | Kim, JH | - |
dc.contributor.author | Roh, JK | - |
dc.contributor.author | Min, JS | - |
dc.contributor.author | Kim, BS | - |
dc.contributor.author | Chung, HC | - |
dc.date.accessioned | 2011-09-06T06:47:52Z | - |
dc.date.available | 2011-09-06T06:47:52Z | - |
dc.date.issued | 1998 | - |
dc.identifier.issn | 1021-335X | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/4049 | - |
dc.description.abstract | We measured the sero-positivity rate of serum alpha-fetoprotein (alphaFP) of gastric cancer patients by ELISA assay; forty-two curatively resected patients, 14 palliatively resected patients, 8 who received explo-laparotomy or bypass surgery and 18 patients with systemic metastasis. The sero-positive rate was 9.8% (8/82) and the positivity increased with cancer progression. Sex, age and pathological type were similar between alphaFP-positive and -negative patients. The overall synchronous hepatic metastasis rates in alphaFP-positive and alphaFP-negative groups were 37.5% (3/8) and 12.2% (9/74), respectively (p=0.08). The predictability of synchronous liver metastasis in eight alphaFP-positive patients were as follows: 37. 5% of total patients (3/8), 50.0% (3/6) of unresectable patients, and 60.0% (3/5) of patients with systemic metastasis. In three alphaFP-positive patient with liver metastasis, all the hepatic lesions were intrahepatic and multiple, while in alphaFP-negative patients, 67% (6/9) of the hepatic lesions was single intrahepatic lesion or surface nodule. The predictability of both synchronous and metachronous liver metastasis in alphaFP-positive gastric cancer patients was 75%. These findings suggested that, in advanced stomach cancer patients, especially in stage IV, alphaFP can be used in predicting liver metastasis during follow-up. | - |
dc.language.iso | en | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Neoplasms | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Palliative Care | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Stomach Neoplasms | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | alpha-Fetoproteins | - |
dc.title | Alpha-fetoprotein-producing gastric cancer. | - |
dc.type | Article | - |
dc.identifier.pmid | 9683831 | - |
dc.identifier.url | http://www.spandidos-publications.com/or/5/5/1179 | - |
dc.contributor.affiliatedAuthor | 최, 진혁 | - |
dc.contributor.affiliatedAuthor | 임, 호영 | - |
dc.type.local | Journal Papers | - |
dc.citation.title | Oncology reports | - |
dc.citation.volume | 5 | - |
dc.citation.number | 5 | - |
dc.citation.date | 1998 | - |
dc.citation.startPage | 1179 | - |
dc.citation.endPage | 1184 | - |
dc.identifier.bibliographicCitation | Oncology reports, 5(5). : 1179-1184, 1998 | - |
dc.identifier.eissn | 1791-2431 | - |
dc.relation.journalid | J01021335X | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.